This page contains a Flash digital edition of a book.
Hunt is a cyborg sent to destroy the NHS


THROUGH THE K HOLE VIEWS


Through the K Hole has a surreal take on the true purpose of health secretary Jeremy Hunt


Rumours that Jeremy Hunt is in fact a merciless cyborg sent by the Tories of the future to destroy what’s left of the NHS have been confirmed today. Scientists working at a top secret lab


have identified a microchip found in one of the health secretary’s socks as a neural-net processor designed by the corporation Skynet.


‘This is truly remarkable,’ says one of the scientists, holding the microchip up to the light. ‘It’s beautifully designed and it confirms what we suspected. The Tories, increasingly frustrated that they can’t just destroy the NHS overnight, sent the cyborg from the distant future, having programmed it with the single, ruthless mission to destroy the health service. And it absolutely will not stop, ever. I just hope he doesn’t get his hands on a plasma rifle otherwise we’re all f*cked.’ Mr Hunt, who was seen wandering around London asking bemused tourists for their clothes, their boots and their motorcycles, had nothing to say other than ‘Come with me if you want to live’.


Dr Kevin Hinkley is a GP in Edinburgh


Get your dose of Pulse on


the go The PulseToday website has been upgraded to be easier to navigate and use on mobile devices, but still has all your favourite content. Take a look at the new Pulse site and register with us for access to all the content at pulsetoday.co.uk


Depo-Medrone®(methylprednisolone is a corticosteroid & Depo-Medrone Lidocaine® (methylprednisolone BP 4%, lidocaine


BP with


hydrochloride BP 1%) is a corticosteroid with an anaesthetic indicated for use in rheumatoid arthritis and osteoarthritis with an infl ammatory component via


intra-articular administration. Please consult


the summary of product characteristics before prescribing Depo-Medrone or Depo-Medrone with Lidocaine, particularly in relation to side effects, precautions and contra-indications.


Information


about these products, including adverse reactions, precautions, contra-indications and method of use can be found at www.medicines.org.uk/emc/medicine/3549 and www.medicines.org.uk/emc/medicine/1502. Legal category: POM. Marketing authorisation holder: Depo-Medrone and Depo-Medrone with Lidocaine: Pfi zer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ. Further information is available on request from: Medical Information at Pfi zer Limited, Walton Oaks, Dorking Road, Tadworth, Surrey, KT20 7NS, UK. Tel: +44 (0) 1304 616161.


Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Pfi zer Medical Information on 01304 616161.


4%)


Methylprednisolone BP 4%


To see more information on injection technique and expert opinion visit www.depomedrone.co.uk or scan QR code


Date of preparation: January 2016 UK/MED/15/0010


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108